vs
Beam Therapeutics Inc.（BEAM）与OneStream, Inc.（OS）财务数据对比。点击上方公司名可切换其他公司
OneStream, Inc.的季度营收约是Beam Therapeutics Inc.的1.4倍（$163.7M vs $114.1M），Beam Therapeutics Inc.净利率更高（214.1% vs 0.6%，领先213.5%），Beam Therapeutics Inc.同比增速更快（279.5% vs 23.6%），OneStream, Inc.自由现金流更多（$25.6M vs $-87.0M）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
Blue Stream面向美国佛罗里达州科勒尔斯普林斯、韦斯顿两地的居民及商业客户，提供有线电视、有线固话、数字录像服务，以及最高速率达1G的宽带互联网接入服务，深耕当地通信市场，为用户提供稳定可靠的多元通信解决方案。
BEAM vs OS — 直观对比
营收规模更大
OS
是对方的1.4倍
$114.1M
营收增速更快
BEAM
高出255.9%
23.6%
净利率更高
BEAM
高出213.5%
0.6%
自由现金流更多
OS
多$112.7M
$-87.0M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $163.7M |
| 净利润 | $244.3M | $999.0K |
| 毛利率 | — | 69.8% |
| 营业利润率 | -15.3% | -3.2% |
| 净利率 | 214.1% | 0.6% |
| 营收同比 | 279.5% | 23.6% |
| 净利润同比 | 370.4% | — |
| 每股收益（稀释后） | $2.53 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMOS
| Q4 25 | $114.1M | $163.7M | ||
| Q3 25 | — | $154.3M | ||
| Q2 25 | — | $147.6M | ||
| Q1 25 | — | $136.3M | ||
| Q4 24 | — | $132.5M | ||
| Q3 24 | — | $129.1M | ||
| Q2 24 | — | $117.5M | ||
| Q1 24 | — | $110.3M |
净利润BEAMOS
| Q4 25 | $244.3M | $999.0K | ||
| Q3 25 | — | $-8.8M | ||
| Q2 25 | — | $-18.4M | ||
| Q1 25 | — | $-24.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-171.9M | ||
| Q2 24 | — | $-7.8M | ||
| Q1 24 | — | $-5.0M |
毛利率BEAMOS
| Q4 25 | — | 69.8% | ||
| Q3 25 | — | 68.1% | ||
| Q2 25 | — | 68.6% | ||
| Q1 25 | — | 68.0% | ||
| Q4 24 | — | 66.8% | ||
| Q3 24 | — | 50.1% | ||
| Q2 24 | — | 68.5% | ||
| Q1 24 | — | 69.1% |
营业利润率BEAMOS
| Q4 25 | -15.3% | -3.2% | ||
| Q3 25 | — | -11.3% | ||
| Q2 25 | — | -21.8% | ||
| Q1 25 | — | -29.3% | ||
| Q4 24 | — | -35.8% | ||
| Q3 24 | — | -197.6% | ||
| Q2 24 | — | -9.8% | ||
| Q1 24 | — | -4.9% |
净利率BEAMOS
| Q4 25 | 214.1% | 0.6% | ||
| Q3 25 | — | -5.7% | ||
| Q2 25 | — | -12.5% | ||
| Q1 25 | — | -17.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -133.1% | ||
| Q2 24 | — | -6.7% | ||
| Q1 24 | — | -4.5% |
每股收益（稀释后）BEAMOS
| Q4 25 | $2.53 | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-1.06 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $693.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $504.7M |
| 总资产 | $1.5B | $1.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BEAMOS
| Q4 25 | $1.2B | $693.6M | ||
| Q3 25 | — | $653.9M | ||
| Q2 25 | — | $652.1M | ||
| Q1 25 | — | $593.9M | ||
| Q4 24 | — | $544.2M | ||
| Q3 24 | — | $495.5M | ||
| Q2 24 | — | $140.5M | ||
| Q1 24 | — | — |
股东权益BEAMOS
| Q4 25 | $1.2B | $504.7M | ||
| Q3 25 | — | $472.1M | ||
| Q2 25 | — | $458.2M | ||
| Q1 25 | — | $412.9M | ||
| Q4 24 | — | $386.2M | ||
| Q3 24 | — | $458.2M | ||
| Q2 24 | — | $97.5M | ||
| Q1 24 | — | $102.5M |
总资产BEAMOS
| Q4 25 | $1.5B | $1.0B | ||
| Q3 25 | — | $949.4M | ||
| Q2 25 | — | $910.5M | ||
| Q1 25 | — | $867.3M | ||
| Q4 24 | — | $823.2M | ||
| Q3 24 | — | $750.1M | ||
| Q2 24 | — | $379.7M | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | $25.8M |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | $25.6M |
| 自由现金流率自由现金流/营收 | -76.3% | 15.7% |
| 资本支出强度资本支出/营收 | 3.3% | 0.1% |
| 现金转化率经营现金流/净利润 | -0.34× | 25.79× |
| 过去12个月自由现金流最近4个季度 | — | $95.6M |
8季度趋势，按日历期对齐
经营现金流BEAMOS
| Q4 25 | $-83.3M | $25.8M | ||
| Q3 25 | — | $5.0M | ||
| Q2 25 | — | $29.7M | ||
| Q1 25 | — | $36.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $2.4M | ||
| Q2 24 | — | $8.1M | ||
| Q1 24 | — | $25.5M |
自由现金流BEAMOS
| Q4 25 | $-87.0M | $25.6M | ||
| Q3 25 | — | $4.8M | ||
| Q2 25 | — | $29.4M | ||
| Q1 25 | — | $35.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | — | $7.7M | ||
| Q1 24 | — | $24.9M |
自由现金流率BEAMOS
| Q4 25 | -76.3% | 15.7% | ||
| Q3 25 | — | 3.1% | ||
| Q2 25 | — | 19.9% | ||
| Q1 25 | — | 26.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 22.5% |
资本支出强度BEAMOS
| Q4 25 | 3.3% | 0.1% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.6% |
现金转化率BEAMOS
| Q4 25 | -0.34× | 25.79× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
OS
| Subscription And Circulation | $150.3M | 92% |
| Professional Services And Other | $9.4M | 6% |
| License | $4.0M | 2% |
